SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): May 9, 2000
Repligen Corporation
---------------------
(Exact name of Registrant as specified in its charter)
117 Fourth Avenue, Needham, Massachusetts
-----------------------------------------
(Address of principal executive offices)
02494
-----
(Zip Code)
(781) 449-9560
---------------
Registrant's telephone number, including area code
No change since last report
---------------------------
(Former name or address, if changed since last report)
Delaware 000-14656 04-2729386
-------- --------- ----------
(State or other jurisdiction of (Commission file (I.R.S. Employer
incorporation or organization) number) Identification No.)
Item 5. Other Events.
- ----------------------
On May 9, 2000, Repligen Corporation (the "Company") entered into an
agreement with Tolerance Therapeutics LLC ("Tolerance") pursuant to which
Tolerance assigned its rights to a patent application claiming the use of
CTLA4-Ig as an immunosuppressive agent.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
- ----------------------------------------------------------------------------
(a) Financial Statements of Business Acquired: None required.
(b) Pro Forma Financial Information: None required.
(c) Exhibits:
---------
Exhibit No. Description
----------- -----------
99.1 Press release of the Company dated May 18, 2000.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
REPLIGEN CORPORATION
By: /S/ Walter C. Herlihy
--------------------------------
Name: Walter C. Herlihy
Title: President and Chief Executive Officer
Date: May 19, 2000
EXHIBIT INDEX
Exhibit No. Description
- ----------- -----------
99.1 Press release of the Company dated May 18, 2000.